Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Draft NICE guidelines propose wider access to glucose monitoring tech
JDRF is delighted that the National Institute for Healthcare and Care Excellence (NICE) has published draft guidelines recommending that all adults with type 1 diabetes should be offered a choice of flash or continuous glucose monitoring (CGM) in England.
The draft guidance also recommends that children with type 1 diabetes are offered CGM in the first instance and if CGM is not suitable, they should then be offered flash monitoring.
Currently, NICE only recommends that flash monitoring or CGM are offered if patients meet certain criteria.
The proposal will now undergo stakeholder consultation before the NICE guidance on type 1 diabetes is updated in March 2022.
The advance follows JDRF’s ongoing work with NICE to expand access to type 1 technology. In 2019, JDRF submitted comments to the NICE stakeholder consultation calling for a change in wording that would require healthcare professionals to ‘offer’ rather than ‘consider’ CGM for people with type 1 diabetes who meet the criteria. This amendment has been incorporated into the draft guidance.
Whilst the recommendations are a positive development, ensuring that Clinical Commissioning Groups (CCGs) and healthcare providers enact the guidance will form a vital part of JDRF’s ongoing advocacy work.
JDRF Policy and Public Affairs Manager, Rachael Chrisp, says: “This is a big step forward and we are hopeful that by spring of next year, these changes will be implemented. We’re proud of the part we’ve played in strengthening NICE guidance on flash and continuous glucose monitoring.
“It’s been a cross-sector effort with outstanding leadership from NHS England’s National Speciality Advisor Professor Partha Kar together with charities such as JDRF, clinicians, researchers and advocates from the type 1 community.
“We know however there is still much to do to ensure that CCGs and healthcare providers take on this guidance so that everyone with type 1 has access to the treatments they want or need across the four nations of the UK.”
NICE guidance applies to England, but is likely to be adopted in Wales and have influence on Scottish and Northern Irish bodies.
JDRF will work with people affected by type 1 diabetes to submit a formal response to the consultation.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
Abbott has announced that its FreeStyle Libre® 3 sensor is now authorised to work with Ypsomed’s mylife™ YpsoPump and CamDiab’s CamAPS FX mobile app.